David L. Bartlett is a board-certified general surgeon who specializes in peritoneal mesothelioma.
- Chief of the institution’s Division of Surgical Oncology and vice chairman for Surgical Oncology and Gastrointestinal services; also serves as vice chairman of the David C. Koch Regional Perfusion Cancer Therapy Center and director of Multidisciplinary Disease Site Clinical and Research Programs for the University of Pittsburgh Cancer Institute.
- Renowned authority on regional therapeutics — the delivery of drugs or therapeutic agents directly to a tumor through its supporting blood vessels.
- Investigating use of lab-engineered viruses that attack and destroy only cancer cells, a process known as tumor-directed gene therapy.
- Developed innovative surgical techniques that resulted in improved patient survival rates and quality of life while at the National Cancer Institute’s Center for Cancer Research; played a prominent role in the development of the hyperthermic intraperitoneal chemoperfusion technique that delivers chemotherapy to only the peritoneal cavity.
- Authored numerous articles on regional treatment strategies and tumor-directed gene therapy published in peer-reviewed journals, including Cancer Research and Journal of the National Cancer Institute; wrote several chapters in textbooks on cancer therapeutics and surgical oncology.
- Teaches at University of Pittsburgh School of Medicine.
- Member of the American Medical Association, Society of Surgical Oncology, Society of Laparoendoscopic Surgeons, American Society of Gene Therapy, Society of University Surgeons, American Society of Clinical Oncology, American Association for Cancer Research, American College of Surgeons, American Surgical Association, American Association for Endocrine Surgeons, and American Society of Peritoneal Surface Malignancies.
- M.D. degree from University of Texas Medical School, Houston.